Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation

American Journal of Human Genetics

Volumn 99, Issue 4, 2016, Pages 903-911

  Ghoussaini, Maya ^a   French, Juliet D ^b   Michailidou, Kyriaki ^a,c   Nord, Silje ^d   Beesley, Jonathan ^b   Canisus, Sander ^e   Hillman, Kristine M ^b   Kaufmann, Susanne ^b   Sivakumaran, Haran ^b   Moradi Marjaneh, Mahdi ^b   Lee, Jason S ^b   Dennis, Joe ^a   Bolla, Manjeet K ^a   Wang, Qin ^a   Dicks, Ed ^a   Milne, Roger L ^f,g   Hopper, John L ^g   Southey, Melissa C ^h   Schmidt, Marjanka K ^e   Broeks, Annegien ^e   Muir, Kenneth ^i,j   Lophatananon, Artitaya ^i,j   Fasching, Peter A ^k,l   Beckmann, Matthias W ^k   Fletcher, Olivia ^m   Johnson, Nichola ^m   Sawyer, Elinor J ⁿ   Tomlinson, Ian ^o   Burwinkel, Barbara ^p,q   Marme, Frederik ^p   Guénel, Pascal ^r   Truong, Thérèse ^r   Bojesen, Stig E ^s,t   Flyger, Henrik ^s   Benitez, Javier ^u,v   González Neira, Anna ^u   Alonso, M Rosario ^u   Pita, Guillermo ^u   Neuhausen, Susan L ^w   Anton Culver, Hoda ^x   Brenner, Hermann ^q   Arndt, Volker ^q   Meindl, Alfons ^y   Schmutzler, Rita K ^z,aa   Brauch, Hiltrud ^q,ab,ac   Hamann, Ute ^q   Tessier, Daniel C ^ad   Vincent, Daniel ^ad   Nevanlinna, Heli ^ae   Khan, Sofia ^ae   Matsuo, Keitaro ^af   Ito, Hidemi ^af   Dörk, Thilo ^ag   Bogdanova, Natalia V ^ag   Lindblom, Annika ^ah   Margolin, Sara ^ah   Mannermaa, Arto ^ai,aj   Kosma, Veli Matti ^ai,aj   Wu, Anna H ^ak   Van Den Berg, David ^ak   Lambrechts, Diether ^al,am   Floris, Giuseppe ^an   Chang Claude, Jenny ^q,ao   Rudolph, Anja ^q   Radice, Paolo ^ap   Barile, Monica ^aq   Couch, Fergus J ^ar   Hallberg, Emily ^ar   Giles, Graham G ^f,g   Haiman, Christopher A ^ak   Le Marchand, Loic ^as   Goldberg, Mark S ^ad,at   Teo, Soo H ^au,av   Yip, Cheng Har ^av   Borresen Dale, Anne Lise ^d   Zheng, Wei ^aw   Cai, Qiuyin ^aw   Winqvist, Robert ^ax,ay   Pylkäs, Katri ^ax,ay   Andrulis, Irene L ^az,ba   Devilee, Peter ^bb   Tollenaar, Rob A E M ^bb   García Closas, Montserrat ^bc   Figueroa, Jonine ^bc,bd   Hall, Per ^ah   Czene, Kamila ^ah   Brand, Judith S ^ah   Darabi, Hatef ^ah   Eriksson, Mikael ^ah   Hooning, Maartje J ^be   Koppert, Linetta B ^be   Li, Jingmei ^ah   Shu, Xiao Ou ^aw   Zheng, Ying ^bf   Cox, Angela ^bg   Cross, Simon S ^bg   Shah, Mitul ^a   Rhenius, Valerie ^a   Choi, Ji Yeob ^bh,bi   Kang, Daehee ^bh,bi   Hartman, Mikael ^bj,bk   Chia, Kee Seng ^bj   Kabisch, Maria ^q   Torres, Diana ^q,bl   Luccarini, Craig ^a   Conroy, Don M ^a   Jakubowska, Anna ^bm   Lubinski, Jan ^bm   Sangrajrang, Suleeporn ^bn   Brennan, Paul ^bo   Olswold, Curtis ^as   Slager, Susan ^as   Shen, Chen Yang ^bp,bq   Hou, Ming Feng ^br   Swerdlow, Anthony ^m   Schoemaker, Minouk J ^m   Simard, Jacques ^bs   Pharoah, Paul D P ^a   Kristensen, Vessela ^d,bt   Chenevix Trench, Georgia ^b   Easton, Douglas F ^a   Dunning, Alison M ^a   Edwards, Stacey L ^b   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^f Centre for Behavioural Research in Cancer   (United States)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j UNIVERSITY OF WARWICK   (United Kingdom)

^k UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁿ GUY S HOSPITAL   (United Kingdom)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p UNIVERSITY OF HEIDELBERG   (Germany)

^q GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^r CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^s GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^t UNIVERSITY OF COPENHAGEN   (Denmark)

^u Structural Biology and Biocomputing Programme   (Spain)

^v Centro de Investigación en Red de Enfermedades Raras   (Spain)

^w CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^x UNIVERSITY OF CALIFORNIA   (United States)

^y TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^z UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^aa UNIVERSITY OF COLOGNE   (Germany)

^ab DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^ac UNIVERSITY OF TÜBINGEN   (Germany)

^ad MCGILL UNIVERSITY   (Canada)

^ae HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^af AICHI CANCER CENTER HOSPITAL   (Japan)

^ag HANNOVER MEDICAL SCHOOL   (Germany)

^ah KAROLINSKA INSTITUTE   (Sweden)

^ai UNIVERSITY OF EASTERN FINLAND   (Finland)

^aj KUOPIO UNIVERSITY HOSPITAL   (Finland)

^ak UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^al DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^am UNIVERSITY OF LEUVEN   (Belgium)

^an UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ao UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^ap NATIONAL CANCER INSTITUTE   (Italy)

^aq EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^ar MAYO CLINIC   (United States)

^as UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^at ROYAL VICTORIA HOSPITAL   (Canada)

^au CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^av UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^aw VANDERBILT INGRAM CANCER CENTER   (United States)

^ax UNIVERSITY OF OULU   (Finland)

^ay Northern Finland Laboratory Centre   (Finland)

^az MOUNT SINAI HOSPITAL   (Canada)

^ba UNIVERSITY OF TORONTO   (Canada)

^bb LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^bc NATIONAL CANCER INSTITUTE   (United States)

^bd UNIVERSITY OF EDINBURGH   (United Kingdom)

^be ERASMUS MC CANCER INSTITUTE   (Netherlands)

^bf Shanghai Municipal Center for Disease Control and Prevention   (China)

^bg UNIVERSITY OF SHEFFIELD   (United Kingdom)

^bh Seoul National University College of Medicine   (South Korea)

^bi Seoul National University   (South Korea)

^bj NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^bk NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^bl PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^bm POMERANIAN MEDICAL UNIVERSITY   (Poland)

^bn NATIONAL CANCER INSTITUTE   (Thailand)

^bo INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^bp CHINA MEDICAL UNIVERSITY   (Taiwan)

^bq INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^br KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^bs University Laval   (Canada)

^bt OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FGF10 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR RECEPTOR 2;

ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ENHANCER REGION; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE CONTROL; GENE MAPPING; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; ONCOGENE FGF10; ONCOGENE MRPS30; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; CASE CONTROL STUDY; CHROMOSOME 5; GENETIC PREDISPOSITION; GENETICS; METABOLISM; TUMOR CELL LINE;

ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 5; ENHANCER ELEMENTS, GENETIC; FIBROBLAST GROWTH FACTOR 10; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; QUANTITATIVE TRAIT LOCI; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, ESTROGEN;

EID: 84991598798     PISSN: 00029297     EISSN: 15376605     Source Type: Journal    
DOI: 10.1016/j.ajhg.2016.07.017     Document Type: Article

References (25)

1. 1 Stacey, S.N., Manolescu, A., Sulem, P., Rafnar, T., Gudmundsson, J., Gudjonsson, S.A., Masson, G., Jakobsdottir, M., Thorlacius, S., Helgason, A., et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39 (2007), 865–869.
2. 2 Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D., Thompson, D., Ballinger, D.G., Struewing, J.P., Morrison, J., Field, H., Luben, R., et al. SEARCH collaborators kConFab, AOCS Management Group. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 (2007), 1087–1093.
3. 3 Hunter, D.J., Kraft, P., Jacobs, K.B., Cox, D.G., Yeager, M., Hankinson, S.E., Wacholder, S., Wang, Z., Welch, R., Hutchinson, A., et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39 (2007), 870–874.
4. 4 Stacey, S.N., Manolescu, A., Sulem, P., Thorlacius, S., Gudjonsson, S.A., Jonsson, G.F., Jakobsdottir, M., Bergthorsson, J.T., Gudmundsson, J., Aben, K.K., et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 40 (2008), 703–706.
5. 5 Milne, R.L., Goode, E.L., García-Closas, M., Couch, F.J., Severi, G., Hein, R., Fredericksen, Z., Malats, N., Zamora, M.P., Arias Pérez, J.I., et al. GENICA Network kConFab Investigators, AOCS Group. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol. Biomarkers Prev. 20 (2011), 2222–2231.
6. 6 Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M., Dennis, J., Milne, R.L., Schmidt, M.K., Chang-Claude, J., Bojesen, S.E., Bolla, M.K., et al. Breast and Ovarian Cancer Susceptibility Collaboration Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) kConFab Investigators Australian Ovarian Cancer Study Group, GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet. 45 (2013), 353–361, e1–e2.
7. 7 Quigley, D.A., Fiorito, E., Nord, S., Van Loo, P., Alnæs, G.G., Fleischer, T., Tost, J., Moen Vollan, H.K., Tramm, T., Overgaard, J., et al. The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors. Mol. Oncol. 8 (2014), 273–284.
8. 8 Ghoussaini, M., Edwards, S.L., Michailidou, K., Nord, S., Cowper-Sal Lari, R., Desai, K., Kar, S., Hillman, K.M., Kaufmann, S., Glubb, D.M., et al. Australian Ovarian Cancer Management Group, Australian Ovarian Cancer Management Group. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat. Commun., 4, 2014, 4999.
9. 9 Li, Q., Seo, J.H., Stranger, B., McKenna, A., Pe'er, I., Laframboise, T., Brown, M., Tyekucheva, S., Freedman, M.L., Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 152 (2013), 633–641.
10. 10 Consortium, G.T., GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45 (2013), 580–585.
11. 11 Birney, E., Stamatoyannopoulos, J.A., Dutta, A., Guigó, R., Gingeras, T.R., Margulies, E.H., Weng, Z., Snyder, M., Dermitzakis, E.T., Thurman, R.E., et al. ENCODE Project Consortium NISC Comparative Sequencing Program Baylor College of Medicine Human Genome Sequencing Center Washington University Genome Sequencing Center Broad Institute, Children's Hospital Oakland Research Institute. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447 (2007), 799–816.
12. 12 Hnisz, D., Abraham, B.J., Lee, T.I., Lau, A., Saint-André, V., Sigova, A.A., Hoke, H.A., Young, R.A., Super-enhancers in the control of cell identity and disease. Cell 155 (2013), 934–947.
13. 13 Corradin, O., Saiakhova, A., Akhtar-Zaidi, B., Myeroff, L., Willis, J., Cowper-Sal lari, R., Lupien, M., Markowitz, S., Scacheri, P.C., Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res. 24 (2014), 1–13.
14. 14 Glubb, D.M., Maranian, M.J., Michailidou, K., Pooley, K.A., Meyer, K.B., Kar, S., Carlebur, S., O'Reilly, M., Betts, J.A., Hillman, K.M., et al. GENICA Network kConFab Investigators, Norwegian Breast Cancer Study. Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. Am. J. Hum. Genet. 96 (2015), 5–20.
15. 15 Dunning, A.M., Michailidou, K., Kuchenbaecker, K.B., Thompson, D., French, J.D., Beesley, J., Healey, C.S., Kar, S., Pooley, K.A., Lopez-Knowles, E., et al. EMBRACE GEMO Study Collaborators HEBON, kConFab Investigators. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat. Genet. 48 (2016), 374–386.
16. 16 Hurtado, A., Holmes, K.A., Ross-Innes, C.S., Schmidt, D., Carroll, J.S., FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43 (2011), 27–33.
17. 17 Cowper-Sal lari, R., Zhang, X., Wright, J.B., Bailey, S.D., Cole, M.D., Eeckhoute, J., Moore, J.H., Lupien, M., Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat. Genet. 44 (2012), 1191–1198.
18. 18 Meyer, K.B., Maia, A.T., O'Reilly, M., Teschendorff, A.E., Chin, S.F., Caldas, C., Ponder, B.A., Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol., 6, 2008, e108.
19. 19 Belikov, S., Astrand, C., Wrange, O., FoxA1 binding directs chromatin structure and the functional response of a glucocorticoid receptor-regulated promoter. Mol. Cell. Biol. 29 (2009), 5413–5425.
20. 20 Cavdar Koc, E., Ranasinghe, A., Burkhart, W., Blackburn, K., Koc, H., Moseley, A., Spremulli, L.L., A new face on apoptosis: death-associated protein 3 and PDCD9 are mitochondrial ribosomal proteins. FEBS Lett. 492 (2001), 166–170.
21. 21 Turner, N., Grose, R., Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 10 (2010), 116–129.
22. 22 Meyer, K.B., O'Reilly, M., Michailidou, K., Carlebur, S., Edwards, S.L., French, J.D., Prathalingham, R., Dennis, J., Bolla, M.K., Wang, Q., et al. GENICA Network kConFab Investigators, Australian Ovarian Cancer Study Group. Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am. J. Hum. Genet. 93 (2013), 1046–1060.
23. 23 Theodorou, V., Boer, M., Weigelt, B., Jonkers, J., van der Valk, M., Hilkens, J., Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene 23 (2004), 6047–6055.
24. 24 Abolhassani, A., Riazi, G.H., Azizi, E., Amanpour, S., Muhammadnejad, S., Haddadi, M., Zekri, A., Shirkoohi, R., FGF10: type III epithelial mesenchymal transition and invasion in breast cancer cell lines. J. Cancer 5 (2014), 537–547.
25. 25 Chioni, A.M., Grose, R., Negative regulation of fibroblast growth factor 10 (FGF-10) by polyoma enhancer activator 3 (PEA3). Eur. J. Cell Biol. 88 (2009), 371–384.